NewsBenzingaVeradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile Veradermics' VDPHL01 Meets All Primary And Secondary Endpoints In Phase 3 Study, Demonstrates Significant Hair Count Gains And Favorable Safety Profile Benzinga 2026.10.19 11:13 (GMT+0) Open on Benzinga Other news T1 Energy Stock Plunges: What's Going On? Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT Nike CEO Says Co Aims To Double The Units Of Product Created In Under 14 Months By FY31